Published in Expert Opin Pharmacother on May 01, 2003
Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrob Agents Chemother (2008) 3.05
In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance. J Clin Microbiol (2006) 2.53
Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment. Antimicrob Agents Chemother (2008) 2.41
Disposition of caspofungin, a novel antifungal agent, in mice, rats, rabbits, and monkeys. Antimicrob Agents Chemother (2004) 1.48
Mechanisms of azole resistance in a clinical isolate of Candida tropicalis. Antimicrob Agents Chemother (2005) 1.21
Msb2 signaling mucin controls activation of Cek1 mitogen-activated protein kinase in Candida albicans. Eukaryot Cell (2009) 1.12
Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis. Antimicrob Agents Chemother (2005) 1.08
Changes in the proteome of Candida albicans in response to azole, polyene, and echinocandin antifungal agents. Antimicrob Agents Chemother (2010) 1.02
Cholesterol import by Aspergillus fumigatus and its influence on antifungal potency of sterol biosynthesis inhibitors. Antimicrob Agents Chemother (2005) 0.98
Quantitative Microplate-Based Growth Assay for Determination of Antifungal Susceptibility of Histoplasma capsulatum Yeasts. J Clin Microbiol (2015) 0.79
In vitro activity and in vivo efficacy of icofungipen (PLD-118), a novel oral antifungal agent, against the pathogenic yeast Candida albicans. Antimicrob Agents Chemother (2006) 0.76
Efficacy, plasma pharmacokinetics, and safety of icofungipen, an inhibitor of Candida isoleucyl-tRNA synthetase, in treatment of experimental disseminated candidiasis in persistently neutropenic rabbits. Antimicrob Agents Chemother (2005) 0.75
Surgery of pulmonary aspergillomas in immunocompromised patients. Thorac Surg Sci (2010) 0.75
Human dectin-1 deficiency and mucocutaneous fungal infections. N Engl J Med (2009) 5.27
Same-sex mating and the origin of the Vancouver Island Cryptococcus gattii outbreak. Nature (2005) 5.11
Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis (2006) 4.88
Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J Clin Microbiol (2004) 4.70
Sexual cycle of Cryptococcus neoformans var. grubii and virulence of congenic a and alpha isolates. Infect Immun (2003) 3.61
Combination antifungal therapy. Antimicrob Agents Chemother (2004) 3.49
The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother (2011) 3.04
Cryptococcosis. Infect Dis Clin North Am (2006) 2.82
Calcineurin is essential for survival during membrane stress in Candida albicans. EMBO J (2002) 2.81
An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med (2011) 2.70
Harnessing calcineurin as a novel anti-infective agent against invasive fungal infections. Nat Rev Microbiol (2007) 2.60
Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis (2008) 2.55
Hsp90 orchestrates temperature-dependent Candida albicans morphogenesis via Ras1-PKA signaling. Curr Biol (2009) 2.50
Breakthrough invasive candidiasis in patients on micafungin. J Clin Microbiol (2010) 2.47
Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. Proc Natl Acad Sci U S A (2009) 2.35
Calcineurin controls growth, morphology, and pathogenicity in Aspergillus fumigatus. Eukaryot Cell (2006) 2.35
Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact. Clin Infect Dis (2008) 2.33
Killing of Caenorhabditis elegans by Cryptococcus neoformans as a model of yeast pathogenesis. Proc Natl Acad Sci U S A (2002) 2.29
Adenylyl cyclase functions downstream of the Galpha protein Gpa1 and controls mating and pathogenicity of Cryptococcus neoformans. Eukaryot Cell (2002) 2.21
CX3CR1-dependent renal macrophage survival promotes Candida control and host survival. J Clin Invest (2013) 2.00
Superoxide dismutase influences the virulence of Cryptococcus neoformans by affecting growth within macrophages. Infect Immun (2003) 2.00
Calcineurin is essential for Candida albicans survival in serum and virulence. Eukaryot Cell (2003) 1.98
Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J (2002) 1.97
Disruption of a nonribosomal peptide synthetase in Aspergillus fumigatus eliminates gliotoxin production. Eukaryot Cell (2006) 1.92
Urease expression by Cryptococcus neoformans promotes microvascular sequestration, thereby enhancing central nervous system invasion. Am J Pathol (2004) 1.87
Comparative evaluation of Etest and sensititre yeastone panels against the Clinical and Laboratory Standards Institute M27-A2 reference broth microdilution method for testing Candida susceptibility to seven antifungal agents. J Clin Microbiol (2007) 1.78
Hsp90 governs echinocandin resistance in the pathogenic yeast Candida albicans via calcineurin. PLoS Pathog (2009) 1.76
Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis (2004) 1.74
When primary antifungal therapy fails. Clin Infect Dis (2008) 1.67
Identification of App1 as a regulator of phagocytosis and virulence of Cryptococcus neoformans. J Clin Invest (2003) 1.66
Immune reconstitution syndrome associated with opportunistic mycoses. Lancet Infect Dis (2007) 1.65
PKC signaling regulates drug resistance of the fungal pathogen Candida albicans via circuitry comprised of Mkc1, calcineurin, and Hsp90. PLoS Pathog (2010) 1.63
Carbonic anhydrase and CO2 sensing during Cryptococcus neoformans growth, differentiation, and virulence. Curr Biol (2005) 1.62
Outcome of lung transplantation in patients with mycetomas. Chest (2002) 1.59
A MAP kinase cascade composed of cell type specific and non-specific elements controls mating and differentiation of the fungal pathogen Cryptococcus neoformans. Mol Microbiol (2003) 1.55
Mating-type-specific and nonspecific PAK kinases play shared and divergent roles in Cryptococcus neoformans. Eukaryot Cell (2002) 1.55
Differential effects of inhibiting chitin and 1,3-{beta}-D-glucan synthesis in ras and calcineurin mutants of Aspergillus fumigatus. Antimicrob Agents Chemother (2008) 1.55
Role of PLB1 in pulmonary inflammation and cryptococcal eicosanoid production. Infect Immun (2003) 1.55
Calcineurin inhibition or mutation enhances cell wall inhibitors against Aspergillus fumigatus. Antimicrob Agents Chemother (2007) 1.54
Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis (2006) 1.54
Iatrogenic fungal meningitis: tragedy repeated. Ann Intern Med (2012) 1.54
Identification of Cryptococcus neoformans temperature-regulated genes with a genomic-DNA microarray. Eukaryot Cell (2004) 1.54
Relationship of the glyoxylate pathway to the pathogenesis of Cryptococcus neoformans. Infect Immun (2002) 1.54
Protection against cryptococcosis by using a murine gamma interferon-producing Cryptococcus neoformans strain. Infect Immun (2007) 1.52
Is it time to abandon the use of amphotericin B bladder irrigation? Clin Infect Dis (2005) 1.51
Metabolic adaptation in Cryptococcus neoformans during early murine pulmonary infection. Mol Microbiol (2008) 1.49
In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus. Antimicrob Agents Chemother (2004) 1.46
Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole. Transplantation (2005) 1.45
Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients. Am J Health Syst Pharm (2009) 1.44
Cryptococcosis in solid organ transplant recipients: current state of the science. Clin Infect Dis (2008) 1.44
In vitro analyses, animal models, and 60 clinical cases of invasive Aspergillus terreus infection. Antimicrob Agents Chemother (2004) 1.44
The calcineurin target, Crz1, functions in azole tolerance but is not required for virulence of Candida albicans. Infect Immun (2004) 1.44
Immune reconstitution syndrome and exacerbation of infections after pregnancy. Clin Infect Dis (2007) 1.43
Characterization and regulation of the trehalose synthesis pathway and its importance in the pathogenicity of Cryptococcus neoformans. Infect Immun (2006) 1.41
Cost-effectiveness of posaconazole versus fluconazole for prevention of invasive fungal infections in U.S. patients with graft-versus-host disease. Am J Health Syst Pharm (2012) 1.41
Gpr1, a putative G-protein-coupled receptor, regulates morphogenesis and hypha formation in the pathogenic fungus Candida albicans. Eukaryot Cell (2004) 1.40
Scedosporium prolificans osteomyelitis in an immunocompetent child treated with voriconazole and caspofungin, as well as locally applied polyhexamethylene biguanide. J Clin Microbiol (2003) 1.39
Calcineurin target CrzA regulates conidial germination, hyphal growth, and pathogenesis of Aspergillus fumigatus. Eukaryot Cell (2008) 1.37
First reported case of Cryptococcus gattii in the Southeastern USA: implications for travel-associated acquisition of an emerging pathogen. PLoS One (2009) 1.34
Cryptococcus neoformans {alpha} strains preferentially disseminate to the central nervous system during coinfection. Infect Immun (2005) 1.33
Cryptococcus gattii: an emerging fungal pathogen infecting humans and animals. Microbes Infect (2011) 1.31
Functional genomics identifies type I interferon pathway as central for host defense against Candida albicans. Nat Commun (2013) 1.31
Comparison and temporal trends of three groups with cryptococcosis: HIV-infected, solid organ transplant, and HIV-negative/non-transplant. PLoS One (2012) 1.30
Risk of fungemia due to Rhodotorula and antifungal susceptibility testing of Rhodotorula isolates. J Clin Microbiol (2003) 1.29
Value of an inhalational model of invasive aspergillosis. Med Mycol (2004) 1.29
Cryptococcus neoformans requires a functional glycolytic pathway for disease but not persistence in the host. MBio (2011) 1.29
Plasminogen alleles influence susceptibility to invasive aspergillosis. PLoS Genet (2008) 1.25
The Cryptococcus neoformans catalase gene family and its role in antioxidant defense. Eukaryot Cell (2006) 1.24
Teaching old drugs new tricks: reincarnating immunosuppressants as antifungal drugs. Curr Opin Investig Drugs (2003) 1.24
Antisense repression in Cryptococcus neoformans as a laboratory tool and potential antifungal strategy. Microbiology (2002) 1.23
Toll-like receptor 1 polymorphisms increase susceptibility to candidemia. J Infect Dis (2012) 1.23
Survival defects of Cryptococcus neoformans mutants exposed to human cerebrospinal fluid result in attenuated virulence in an experimental model of meningitis. Infect Immun (2010) 1.22
Role of alternative oxidase gene in pathogenesis of Cryptococcus neoformans. Infect Immun (2003) 1.22
Transcriptional regulation of chitin synthases by calcineurin controls paradoxical growth of Aspergillus fumigatus in response to caspofungin. Antimicrob Agents Chemother (2010) 1.21
The trehalose synthesis pathway is an integral part of the virulence composite for Cryptococcus gattii. Infect Immun (2009) 1.21
Early treatment of candidemia in adults: a review. Med Mycol (2010) 1.21
Cryptococcus neoformans mitochondrial superoxide dismutase: an essential link between antioxidant function and high-temperature growth. Eukaryot Cell (2005) 1.20
Phylogenomic analysis of non-ribosomal peptide synthetases in the genus Aspergillus. Gene (2006) 1.19
Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. Clin Infect Dis (2007) 1.17
Risk factors for mortality in patients with mucormycosis. Med Mycol (2012) 1.13
The Cryptococcus neoformans transcriptome at the site of human meningitis. MBio (2014) 1.11
Peroxisome function regulates growth on glucose in the basidiomycete fungus Cryptococcus neoformans. Eukaryot Cell (2006) 1.10
Pharmacokinetics and pharmacodynamics of fluconazole for cryptococcal meningoencephalitis: implications for antifungal therapy and in vitro susceptibility breakpoints. Antimicrob Agents Chemother (2013) 1.09
Blood gene expression signatures predict invasive candidiasis. Sci Transl Med (2010) 1.08
In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and nontransplant patients. Antimicrob Agents Chemother (2004) 1.08
A meta-analysis of medical versus surgical therapy for Candida endocarditis. J Infect (2004) 1.08
Rare and emerging fungal pulmonary infections. Semin Respir Crit Care Med (2008) 1.07
Cryptococcus neoformans mitochondrial genomes from serotype A and D strains do not influence virulence. Curr Genet (2004) 1.06
Variation in chromosome copy number influences the virulence of Cryptococcus neoformans and occurs in isolates from AIDS patients. BMC Genomics (2011) 1.06
Real-time treatment guidelines: considerations during the Exserohilum rostratum outbreak in the United States. Antimicrob Agents Chemother (2013) 1.04
Surfactant protein D increases phagocytosis of hypocapsular Cryptococcus neoformans by murine macrophages and enhances fungal survival. Infect Immun (2009) 1.04
Deletion of Cryptococcus neoformans AIF ortholog promotes chromosome aneuploidy and fluconazole-resistance in a metacaspase-independent manner. PLoS Pathog (2011) 1.03
Genetic variation in the dectin-1/CARD9 recognition pathway and susceptibility to candidemia. J Infect Dis (2011) 1.02
Evaluation and management of fungal infections in immunocompromised patients. Dermatol Ther (2005) 1.02
Cryptococcus gattii virulence composite: candidate genes revealed by microarray analysis of high and less virulent Vancouver island outbreak strains. PLoS One (2011) 1.02
Quantitation of Candida CFU in initial positive blood cultures. J Clin Microbiol (2011) 1.02
The (1,3){beta}-D-glucan test as an aid to early diagnosis of invasive fungal infections following lung transplantation. J Clin Microbiol (2010) 1.01
β-D-glucan surveillance with preemptive anidulafungin for invasive candidiasis in intensive care unit patients: a randomized pilot study. PLoS One (2012) 1.00
Cytokine gene polymorphisms and the outcome of invasive candidiasis: a prospective cohort study. Clin Infect Dis (2011) 1.00